



TEG[®]

5000 Hemostasis System

TEG[®] Analytical Software



Software Highlights*

- *New Platelet Mapping™ support for antiplatelet therapy monitoring ★*
- *Exceptional support for clinical decisions through hemostasis trend management*
- *More comprehensive reports including case summary ★*
- *Enhanced quality control, including Levey-Jennings reports and out-of-range warnings. ★*

** Look for the "★" to see the latest features of Version 4.*



Version 4
Software





TEG[®] Analytical Software

Enhancing and Simplifying Hemostasis Management

Clinical Enhancements

Reliable Support for Critical Decision-making

TEG Analytical Software Version 4 delivers quantitative and qualitative profiles of hemostasis conditions. Using trend management, the software guides you in patient hemostasis management by:

- Reporting hemostasis trends
- Providing assistance for accurate interpretation
- Showing differential display options
- Highlighting clinical trigger values.

New Assays for Platelet Mapping ★

Two new assays measure the effects of:

- TxA2 inhibitors, such as aspirin
- ADP inhibitors, such as clopidogrel (Plavix) and ticlopidine (Ticlid)
- GPIIb/IIIa inhibitors, such as abciximab (ReoPro), tirofiban (Integrilin), and eptifibatid (Aggrastat).

The software calculates the percent of platelet function reduction due to antiplatelet drugs. This helps you:

- Determine the effect of and monitor antiplatelet therapy
- Evaluate %MA reduction against the patient's own hemostatic/prothrombotic state
- Review trends by viewing clusters of previous Platelet Mapping tracings.

(See the Platelet Mapping brochure for more details.)

Connectivity

TEG Version 4 supports real-time, remote viewing throughout the hospital. Run samples wherever you need them — in the lab, OR, or ICU — or view them wherever you are. The software:

- Accommodates read-only users ★
- Delivers HIS/LIS compatibility
- Provides offline reports via eConsult
- Supports e-mailing of tracings and databases.

Look for the "★" to see the latest features of Version 4.

TEG Version 4 software delivers the data you need for effective hemostasis management — along with the quality control features and flexibility that establish the TEG 5000 Hemostasis System as a powerful tool you can rely on for better patient care.

The advanced Thrombelastograph® (TEG®) 5000 Hemostasis System provides quantitative and qualitative measurements of your patient's hemostasis state using whole blood samples.

QC Improvements

Additional Features that Facilitate Quality Control

TEG Version 4 software offers a variety of features that ease and enhance the quality control process. These functions offer:

- Password-protected operator access ★
- Tracking of logged-in users to create an audit trail ★
- Maintenance and service reports ★
- Ability to display only user-selected channels ★
- Reminders to run control samples ★
- Alerts when controls are out-of-range and capture of operator corrective action ★
- User-specified timeouts after inactivity, requiring operator login to reactivate ★
- Electronics testing.

Functions that Simplify Operation

Several new capabilities make Version 4 easier to operate — and the data more flexible. Look for these useful functions and resources:

- eConsult allows you to send a “flash” report with tracings and numeric data via email to PCs, PDAs and cell phones *
- “Sort” feature rearranges screen data by any field, e.g. patient name ★
- Export feature sends numeric data to Excel spreadsheets and graphs to PowerPoint or Word through standard Windows-based interfaces.
- The Troubleshooting Guide facilitates smooth operation by providing a thorough reference for resolving issues, along with possible causes and remedies. ★

** Destination device must be able to receive and view graphics via email.*

Now Version 4 of the TEG Analytical Software adds powerful features that enhance utility and functionality. This innovative software captures and reports the information you need for effective hemostasis management and includes new case reporting and quality assurance functions.

Case Summary Reporting

1

TEG® Hemostasis Summary
Generated: 8/14/2004 3:13:19 PM

Patient
Name: summary, example Gender: M Age: 56 Weight (kg): 87

Procedure
Name: aa repair Surgeon: Dr. Surgeon
Type: cv Anesthesiologist: Dr. Anesthesiologist
Start: 7/18/2001 11:55:34 AM Pathologist: Dr. Pathologist
End: 7/18/2001 4:04:34 PM Hematologist:
Perfusionist:

2

Coagulation Profile

	baseline	on pump	rewarming	post protamine	icu
R (min)	3.53	7.73	7.72	8.05	4.62
Angle (deg)	54.50	29.50	29.50	60.00	72.00
MA (mm)	44.00	25.00	22.50	57.00	64.00
G (d/sc)	3.93K	1.67K	1.45K	6.63K	8.89K



3

Plat. Inhibition					

4

Blood Products

Type	Amount	Units	Total	Date
platelets	12.00	u	12.00	7/18/2001 5:30:00 PM



- 1: Patient and procedure information is reported.
- 2: The Coagulation Profile is a numeric summary of trends using TEG and non-TEG data. You choose the parameters that are most meaningful.
- 3: Evaluate platelet mapping results.
- 4: See a summary of pharmaceuticals and blood products given.
- 5: Trends for individual parameters are graphed over time.
- 6: Individual TEG tracings are displayed chronologically.


Comprehensive Case Summary ★

TEG Version 4 software generates Case Summary Reports that provide you with a bird's-eye view of patient hemostasis status during the course of an intervention. This easy-to-read report provides:

- Graphical/numeric TEG data and numeric non-TEG test data ★
- Effects of blood products and pharmaceuticals ★
- Case notes ★
- Graphs displaying trends for user-selected TEG- and non-TEG tests with indicators of when blood products and Rx were administered. ★

In cardiovascular surgery, cardiology procedures, organ transplant, obstetrics, trauma and other applications, TEG software helps you more accurately and easily assess risk of both hemorrhage and thrombosis and improve clinical outcomes.

Levey-Jennings Reporting



TEG® Analyzer QC Summary Report
Level 1 Lot Levy-Jennings Interval 3/1/2003 – 3/31/2003

2

Date	Time	R (min)	K (min)	Angle (deg)	MA (mm)	Op	Action	Ch	SN
3/3/2003	9:30:13AM	1.25	0.83	83.59	52.37	Robert		7	0011-974-HBB
3/3/2003	10:02:33AM	1.08	0.83	83.96	52.95	Robert	3	1	0011-275-HBB
3/3/2003	10:02:52AM	1.08	0.83	83.67	52.39	Robert		2	0011-275-HBB
3/3/2003	10:03:21AM	1.17	0.83	82.78	47.66	Robert		3	0011-283-HBB
3/3/2003	10:03:39AM	1.08	0.83	83.64	50.68	Robert		4	0011-283-HBB
3/3/2003	10:04:54AM	1.17	0.83	84.14	53.98	Robert		7	0011-974-HBB
3/3/2003	10:55:29AM	1.33	0.83	83.93	54.27	Robert		4	0011-283-HBB
3/3/2003	10:55:49AM	1.25	0.83	83.10	51.27	Robert		3	0011-283-HBB
3/3/2003	11:51:08AM	1.17	0.83	83.27	49.16	Robert		3	0011-283-HBB
3/3/2003	11:51:25AM	1.17	0.83	84.31	54.31	Robert		4	0011-283-HBB
	Mean	1.11	0.83	83.68	50.92				
	SD	0.1	0	0.7	4.04				
	CV	8.77	0	0.84	7.94				
	n	191	191	191	183				

3

4

1: Graphical display by parameter for each control/lot number

2: All values, by day, with operator ID

3: Corrective actions required by out-of-range values

4: Monthly statistics.

QC Improvement: Levey-Jennings Reporting ★

When it comes to quality assurance, TEG Version 4's clear advantage is the ability to generate Levey-Jennings reports with ease. This report allows you to:

- Quickly spot outliers
- Identify systematic errors
- Discern QC trends for major parameters.

For more information, visit www.haemoscope.com.



Haemoscope Corporation
6231 West Howard Street
Niles, Illinois 60714-3403 USA
www.haemoscope.com

800 GET A TEG (438 2 834)
847.588.0453 phone
847.588.0455 fax
info@haemoscope.com

home of the TEG® hemostasis system